Kalaris Therapeutics Inc
KLRS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $9,126 | $8,440 | $6,030 | $320 |
| G&A Expenses | $3,615 | $3,816 | $4,324 | $0 |
| SG&A Expenses | $3,615 | $3,816 | $4,324 | $19,204 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $12,741 | $12,256 | $10,354 | $19,524 |
| Operating Income | -$12,741 | -$12,256 | -$10,354 | -$19,524 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $847 | $906 | $158 | $1,256 |
| Pre-Tax Income | -$11,894 | -$11,350 | -$10,196 | -$18,268 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11,894 | -$11,350 | -$10,196 | -$18,268 |
| % Margin | – | – | – | – |
| EPS | -0.64 | -0.61 | -2.52 | -3.64 |
| % Growth | -4.9% | 75.8% | 30.8% | – |
| EPS Diluted | -0.64 | -0.61 | -2.52 | -3.64 |
| Weighted Avg Shares Out | 18,702 | 18,701 | 4,053 | 5,020 |
| Weighted Avg Shares Out Dil | 18,702 | 18,701 | 4,053 | 5,020 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1,386 |
| Interest Expense | $0 | $0 | $1,443 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$11,894 | -$11,350 | -$8,753 | -$18,268 |
| % Margin | – | – | – | – |